<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="26894">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02756624</url>
  </required_header>
  <id_info>
    <org_study_id>15-100-0010</org_study_id>
    <nct_id>NCT02756624</nct_id>
  </id_info>
  <brief_title>A Multi-Center, Vehicle-Controlled, Parallel-Group Study Evaluating the Safety of AC-170 Ophthalmic Solution</brief_title>
  <official_title>A Multi-Center, Double-Masked, Randomized, Vehicle-Controlled, Parallel-Group Study Evaluating the Safety of AC-170 Ophthalmic Solution</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nicox Ophthalmics, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ORA, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Nicox Ophthalmics, Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is study is evaluating the safety and tolerability of AC-170 Ophthalmic Solution
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Central Cornea Endothelial Cell Counts will be done on a subset of approximately 150
      subjects to complete 100 subjects as part of the safety measures.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2016</start_date>
  <completion_date type="Actual">August 2016</completion_date>
  <primary_completion_date type="Actual">August 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tolerability of AC 170 0.24% compared to its vehicle</measure>
    <time_frame>up to 6 weeks</time_frame>
    <description>Tolerability of AC 170 0.24% compared to its vehicle will be measured through the 6 week treatment period. Subjects (10 years of age or older) will assess their comfort based on an approved scale.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of treatment related Adverse Events</measure>
    <time_frame>up to 12 weeks</time_frame>
    <description>Adverse events will be measured through study completion</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">516</enrollment>
  <condition>Healthy Subjects</condition>
  <arm_group>
    <arm_group_label>AC-170 0.24%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 drop in each eye 3 times daily for up to 6 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AC-170 Vehicle</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>1 drop in each eye 3 times daily for up to 6 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AC-170 0.24%</intervention_name>
    <arm_group_label>AC-170 0.24%</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AC-170 Vehicle</intervention_name>
    <arm_group_label>AC-170 Vehicle</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  at least 2 years of age

          -  be able to self-administer eye drops or have a parent/legal guardian available for
             this purpose

          -  if less than 18 years old have a history or family history of atopic disease
             (including allergic conjunctivitis)

          -  have ocular health within normal limits

        Exclusion Criteria:

          -  known contraindications or sensitivities to the study medication or its components

          -  any ocular condition that, in the opinion of the investigator, could affect the
             subjects safety trial parameters

          -  use of disallowed medication during the period indicated prior to the enrollment or
             during the study

          -  be pregnant, nursing, or planning a pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Ora Clinical Site Network</name>
      <address>
        <city>Andover</city>
        <state>Massachusetts</state>
        <zip>01810</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <lastchanged_date>September 6, 2016</lastchanged_date>
  <firstreceived_date>April 20, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cetirizine</mesh_term>
    <mesh_term>Ophthalmic Solutions</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
